share_log

Will Weakness in WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock Prove Temporary Given Strong Fundamentals?

Will Weakness in WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock Prove Temporary Given Strong Fundamentals?

無錫藥明康德有限公司會出現弱勢嗎鑑於基本面強勁,s(SHSE: 603259)股票被證明是暫時的?
Simply Wall St ·  04/26 08:18

WuXi AppTec (SHSE:603259) has had a rough three months with its share price down 37%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on WuXi AppTec's ROE.

藥明康德(上海證券交易所代碼:603259)經歷了艱難的三個月,其股價下跌了37%。但是,仔細觀察其良好的財務狀況可能會讓你重新考慮。鑑於基本面通常會推動長期市場業績,因此該公司值得關注。在本文中,我們決定重點介紹藥明康德的投資回報率。

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

股本回報率或投資回報率是用於評估公司管理層利用公司資本效率的關鍵指標。簡而言之,它用於評估公司相對於其股權資本的盈利能力。

How Do You Calculate Return On Equity?

你如何計算股本回報率?

The formula for ROE is:

ROE 的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益

So, based on the above formula, the ROE for WuXi AppTec is:

因此,根據上述公式,藥明康德的投資回報率爲:

17% = CN¥9.7b ÷ CN¥56b (Based on the trailing twelve months to December 2023).

17% = 97億元人民幣 ÷ 56億元人民幣(基於截至2023年12月的過去十二個月)。

The 'return' is the amount earned after tax over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.17.

“回報” 是過去十二個月的稅後收入。因此,這意味着該公司每投資1元人民幣,就會產生0.17元人民幣的利潤。

Why Is ROE Important For Earnings Growth?

爲什麼投資回報率對收益增長很重要?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

到目前爲止,我們已經了解到,投資回報率是衡量公司盈利能力的指標。然後,我們能夠評估公司的收益增長潛力,具體取決於公司對這些利潤進行再投資或 “保留” 了多少及其有效性。假設其他條件都一樣,與功能不相同的公司相比,具有更高股本回報率和更高利潤保留率的公司通常具有更高的增長率。

WuXi AppTec's Earnings Growth And 17% ROE

藥明康德的收益增長和17%的投資回報率

To begin with, WuXi AppTec seems to have a respectable ROE. Especially when compared to the industry average of 7.7% the company's ROE looks pretty impressive. This probably laid the ground for WuXi AppTec's significant 37% net income growth seen over the past five years. We reckon that there could also be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.

首先,藥明康德的投資回報率似乎相當不錯。特別是與7.7%的行業平均水平相比,該公司的投資回報率看起來相當可觀。這可能爲藥明康德在過去五年中實現37%的顯著淨收入增長奠定了基礎。我們認爲,這裏可能還有其他因素在起作用。例如,該公司的派息率較低或管理效率很高。

We then compared WuXi AppTec's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 23% in the same 5-year period.

然後,我們將藥明康德的淨收入增長與該行業進行了比較,我們很高興地看到,與同期5年同期增長率爲23%的行業相比,該公司的增長數字更高。

past-earnings-growth
SHSE:603259 Past Earnings Growth April 26th 2024
SHSE: 603259 過去的收益增長 2024 年 4 月 26 日

Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about WuXi AppTec's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

收益增長是對股票進行估值時要考慮的重要指標。對於投資者來說,重要的是要知道市場是否對公司的預期收益增長(或下降)進行了定價。然後,這可以幫助他們確定股票是面向光明還是暗淡的未來。如果你想知道藥明康德的估值,可以看看這個衡量其市盈率與行業相比的指標。

Is WuXi AppTec Making Efficient Use Of Its Profits?

藥明康德是否在有效利用其利潤?

WuXi AppTec has a three-year median payout ratio of 28% (where it is retaining 72% of its income) which is not too low or not too high. By the looks of it, the dividend is well covered and WuXi AppTec is reinvesting its profits efficiently as evidenced by its exceptional growth which we discussed above.

藥明康德的三年派息率中位數爲28%(保留了收入的72%),這並不太低或不太高。從表面上看,股息覆蓋範圍很大,無錫AppTec正在有效地對其利潤進行再投資,我們上面討論的其出色增長就證明了這一點。

Besides, WuXi AppTec has been paying dividends over a period of five years. This shows that the company is committed to sharing profits with its shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 25%. Accordingly, forecasts suggest that WuXi AppTec's future ROE will be 16% which is again, similar to the current ROE.

此外,藥明康德已經在五年內派發了股息。這表明該公司致力於與股東分享利潤。我們最新的分析師數據顯示,公司未來三年的派息率預計約爲25%。因此,預測表明,藥明康德未來的投資回報率將爲16%,與目前的投資回報率相似。

Summary

摘要

Overall, we are quite pleased with WuXi AppTec's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

總的來說,我們對藥明康德的表現非常滿意。特別是,我們喜歡該公司對其業務進行大量再投資,而且回報率很高。毫不奇怪,這帶來了令人印象深刻的收益增長。話雖如此,最新的行業分析師預測顯示,該公司的收益增長預計將放緩。要了解有關公司未來收益增長預測的更多信息,請查看這份關於分析師預測的免費報告,以了解更多信息。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論